Case Report

Usefulness of a colonic stent for colonic obstruction caused by lung cancer metastasis

Running title: Colonic stent for lung cancer metastasis

Mikito Suzuki¹, Katsuji Okada², Nobuatsu Koyama¹,

Naoyuki Yamashita¹, Aya Yamagishi¹, Takeshi Yamada³, Hiroshi Yoshida³

¹ Department of Surgery, Tsuboi Hospital

² Department of Gastroenterology, Tsuboi Hospital

³ Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery,
Nippon Medical School

Correspondence and Reprint requests:

Mikito SUZUKI, M.D.

Department of Surgery, Tsuboi Hospital

1-10-13 Nagakubo, Asaka-town, Koriyama-city, Hukushima 963-0197, Japan

Phone: +81-024-946-0808

Fax: +81-024-947-0035

E-mail: mkt1118@nms.ac.jp

Abstract

The gastrointestinal tract is not a common site for metastasis from lung cancer, and colonic metastases are especially rare. Although surgical intervention can improve colonic obstruction, perioperative mortality is high in patients with advanced malignancy, and these patients experience a significant deterioration in quality of life postoperatively. This report describes an uncommon case of colonic metastasis from non-small cell lung cancer (NSCLC), in which colonic obstruction was improved with a self-expanding metallic stent.

A 62-year-old man was admitted to our hospital for progressively worsening abdominal pain. He had been treated with immunotherapy and chemotherapy after being diagnosed with NSCLC (T4N2M1) 1.5 years earlier. Enhanced computed tomography showed intestinal obstruction and a mass in the colon at the hepatic flexure. Histopathological analysis of a biopsy specimen confirmed NSCLC metastasis. Considering his general condition, endoscopic stenting was chosen as an urgent decompression procedure. He was discharged 45 days after stenting and was able to resume immunotherapy.

Emergent stenting could be offered at experienced centers when operative intervention is not part of the treatment plan, as it is safe and improves the efficiency of care along with the quality of life.

Key words: lung cancer, colonic metastasis, self-expanding metallic stent

Introduction

Approximately 30%–40% of lung cancers are metastatic at the time of diagnosis^{1,2}, but metastasis to the gastrointestinal tract, especially the colon, is uncommon³. If intestinal obstruction is exacerbated and the general condition is poor because of advanced or metastatic cancer, a self-expanding metallic stent (SEMS) can help to maintain the quality of life without complications. Here, we report a rare case of colonic metastasis from non-small cell lung cancer (NSCLC), in which colonic obstruction was improved by SEMS placement.

Case Report

A 62-year-old man was admitted to our hospital for progressively worsening abdominal pain in January 2020. He had received immunotherapy (pembrolizumab: 200 mg/m²), chemotherapy (carboplatin: area under the curve = 6, pemetrexed: 500 mg/m², and bevacizumab: 15 mg/kg), and radiation therapy for bone metastases after being diagnosed with NSCLC (T4N2M1, right adrenal gland, bone) in September 2018 (Fig. 1). Laboratory tests revealed slight anemia (hematocrit: 39%, hemoglobin: 12.6 g/dL), a leukocyte count of $60 \times 10^2/\mu\text{L}$, a platelet count of $23.7 \times 10^4/\mu\text{L}$, and elevated C-reactive protein (4.72 mg/dL) and alkaline phosphatase (887 IU/L) levels. Enhanced computed tomography (CT) showed a mass in the colon at the hepatic flexure and intestinal dilatation proximal to the lesion (Fig. 2). Colonoscopy revealed a bulky tumor at the hepatic flexure.

Surgery was anticipated to be difficult because the tumor was located at the hepatic flexure and may have invaded organs such as the gallbladder, duodenum, and common bile duct. Moreover, the patient was considered unsuitable for surgery because his general condition was poor and his cancer was advanced with multiple metastases. Accordingly, we decided to place a colonic SEMS.

After acquisition of biopsy specimens, the stenosis was opened using a 22-mm/9-cm through-the-scope SEMS (HANAROSTENT Naturfit™, Boston Scientific) (Fig. 3). His occlusive symptoms were relieved immediately after SEMS placement. He passed flatus the following day and commenced an oral diet 3 days after the treatment. Although his post-treatment course was uneventful, his performance status remained significantly poor; thus, rehabilitation was prolonged. He was discharged 45 days after SEMS placement.

Hematoxylin and eosin staining of the primary lung tumor revealed large, polymorphic cells as well as densely infiltrating and proliferating, atypical cells with distinct nucleoli. Immunostaining revealed that the tumor was positive for AE1/3, vimentin, and cytokeratin (CK) 7 and negative for CK5/6, thyroid transcription factor-1 (TTF-1), Napsin-A, p40, CD56, CK20, and caudal type homeobox 2(CDX-2) (Fig. 4). These findings indicated that the primary lung cancer was NSCLC. Meanwhile, histopathological examination of the colonic biopsies revealed large cells with polymorphic nuclei, typical of primary lung

cancers. Immunostaining showed results identical to those for the lung cancer (Fig. 5). On the basis of these findings, we concluded that the colonic obstruction was caused by metastasis from the lung cancer.

Immunotherapy (nivolumab: 240 mg/m²) was initiated after discharge. Six months after SEMS placement, at the time of writing this report, the patient was alive without recurrence of bowel obstruction and continued to receive immunotherapy.

Discussion

Distant metastases from lung cancer are frequently found in the bone, lung, brain, liver, and adrenal glands. However, metastasis to the colon is rare, accounting for only 0.1% of all colorectal tumors³. Taira et al. reported that among 2066 lung cancer patients, only seven (0.33%) and two (0.09%) had gastrointestinal and colonic metastases, respectively⁴. Tamura et al. reported that only one (0.1%) of 729 NSCLC patients with distant metastases had colonic metastases⁵.

The exact prevalence of colonic metastasis from lung cancer is difficult to determine. According to several autopsy studies, asymptomatic colonic metastasis occurs in approximately 12% of lung cancer patients^{6,7,8}. This high percentage suggests that colonic metastases are often overlooked by clinicians treating lung cancers because of their rarity and lack of characteristic findings on ultrasonography and abdominal CT. If symptoms such as abdominal pain

occur, they are thought to be caused by conditions such as enteritis, gastric ulcer, and cholecystitis; therefore, physicians generally do not perform careful examination. In addition, the patient might have died from other organ metastases or complications before the appearance of colonic metastasis. Compared with colonic metastasis, small intestinal metastasis from lung cancer is more commonly reported⁹. This is because the small intestine has a thinner wall and a smaller lumen than does the large intestine, resulting in a higher frequency of serious complications such as perforation and intestinal obstruction^{10,11}. Therefore, detection of metastases in the small intestine is more likely than detection of metastases in the large intestine.

In this case, the primary lung tumor was diagnosed as NSCLC. Because immunostaining showed negativity for both CD5/6 and p40, it was less likely to be a squamous cell carcinoma. Furthermore, adenocarcinoma was unlikely because immunostaining showed negativity for both TTF-1 and Napsin-A. The CD56 negativity also ruled out a neuroendocrine tumor. On the other hand, the tumor was positive for vimentin and AE 1/3, which indicated a high possibility of large cell carcinoma or sarcoma¹². However, we could not make a definitive diagnosis because this case was diagnosed by bronchoscopy, and surgical resection is required for definitive diagnosis.

Malignant colorectal obstruction is an emergency condition that requires early decompression. Surgical intervention such as colostomy or SEMS is performed as palliative treatment. The 2019 Japanese Society for Cancer of the Colon and

Rectum guidelines mention that stent treatment should be carefully considered while the patient is being treated or has been treated with antiangiogenic therapy such as bevacizumab¹³. Similarly, the 2020 European Society of Gastrointestinal Endoscopy guidelines for SEMS do not suggest colonic stenting while patients are receiving antiangiogenic therapy such as bevacizumab¹⁴. In this case, the patient had been treated with bevacizumab. Thus, colonic stenting should have been carefully considered because of the high risk of perforation and penetration. However, as mentioned earlier, his general condition was poor and he was unsuitable for surgery. In addition, the tumor location at the hepatic flexure could complicate surgery. Therefore, colonic stenting was performed after completing the necessary informed consent procedure.

Currently, three types of SEMS can be used; these include Niti-S™ (Century Medical), WallFlex™ (Boston Scientific), and HANAROSTENT Naturfit™ (Boston Scientific). The HANAROSTENT Naturfit™ is a large intestinal stent sold by Boston Scientific since July 2017. It has available outer diameters of 20 mm and 22 mm and lengths of 6, 9, and 12 cm¹⁵. At present, there are only two reports regarding the use of the HANAROSTENT Naturfit™ for colonic obstruction caused by colorectal cancer. Hashimoto et al. reported the use of HANAROSTENT Naturfit™ in two patients. Technical and clinical success was achieved in both patients, and there was no recurrence of colorectal obstruction for 4 months¹⁶. Ishibashi et al. also reported the use of the

HANAROSTENT Naturfit™ in six patients, only one of whom developed colonic perforation¹⁷. To our knowledge, the case of colonic metastasis from lung cancer has been performed surgery or chemotherapy, or palliative treatment^{18,19,20}. Thus, our case might be the first report of using SEMS for colonic obstruction caused by lung cancer metastasis.

Several meta-analyses comparing SEMS and surgical intervention have shown that SEMS is superior to surgery with respect to short-term complications and shorter hospital stays. However, long-term complications such as perforation, stent migration, and stent obstruction are frequently reported in patients with SEMS^{21,22,23}. This is because a longer survival time is achieved, and patients can continue treatments such as chemotherapy or immunotherapy. According to Liang et al., the incidence of perforation was 3.7% in the short term and 7.6% in the long term. They also reported that the incidence of stent migration was 8.9%²⁴. In addition, Watt et al. reported that the median rate of stent obstruction was 12%, and it occurred from 48 hours to 480 days after placement²². Ono et al. analyzed 50 cases of colorectal metastases from lung cancer and compared the median survival time between the surgery group and non-surgery groups. Although a longer survival time was achieved in the surgery group (90.5 vs 45.0 days), the difference was not statistically significant ($p = 0.054$)²⁵. Although the utility of abdominal surgery in such cases remains controversial, the findings

from this case suggest that SEMS placement is more useful than surgery for palliative treatment.

Because colonic metastasis from lung cancer is the terminal stage of the cancer, radical resection is rarely performed. Lee et al. reported that the average time from gastrointestinal metastasis to death was 2.8 months²³. Moreover, Ishibashi et al. reported that most patients who underwent surgical intervention died within 1 year after the operation²⁶. Thus, we suggest that the indications for surgical intervention should be carefully considered, and that SEMS is more useful than surgery.

Conclusion

This case report describes a rare case of colonic obstruction caused by metastasis from primary lung cancer. Instead of surgery, a colonic stent was placed, and the post-treatment course was uneventful. The patient retained a good quality of life and could receive immunotherapy. Therefore, we suggest that colonic stents are more useful than surgery in such cases.

Acknowledgments: The authors thank Dr. Seiji Igarashi and Miho Kobayashi for assistance with the pathological findings. We also would like to thank Editage (www.editage.com) for English language editing.

Conflict to Interest: The authors declare no conflicts of interest.

References

- 1) Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. *Jpn J Clin Oncol*. 2014 Apr; 44(4): 388-96.
- 2) Little AG, Gay EG, Gaspar LE, Stewart AK. National Survey of Non-Small Cell Lung Cancer in the United States: Epidemiology, Pathology and Patterns of Care. *Lung Cancer*. 2007 Sep; 57(3): 253-60.
- 3) Uehara K, Iijima K, Hasegawa S. Gastrointestinal Metastasis of Lung Cancer -Examination of 1775 Lung Cancer Autopsy Cases-. *Surgery*. 1979; 41(12); 1364-7.
- 4) Taira N, Kawabata T, Gabe A, et al. Analysis of gastrointestinal metastasis of primary lung cancer: Clinical characteristics and prognosis. *Oncol Lett*. 2017 Aug; 14(2): 2399-404.
- 5) Tamura T, Kurishima K, Nakazawa K et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. *Mol Clin Oncol*. 2015 Jan; 3(1): 217-21.
- 6) Kim MS, Kook EH, Ahn SH, et al. Gastrointestinal metastasis of lung cancer with special emphasis on a long-term survivor after operation. *J Cancer Res Clin Oncol*. 2009 Feb; 135(2): 297-301.
- 7) Yoshimoto A, Kasahara K, Kawashima A. Gastrointestinal metastasis from primary lung cancer. *Eur J Cancer*. 2006 Aug ;42(18): 3157-60.

- 8) Hu Y, Feit N, Huang Y, Xu W, Zheng S, Li X. Gastrointestinal metastasis of primary lung cancer: An analysis of 366 cases. *Oncol Lett*. 2018 Jun; 15(6): 9766-76.
- 9) Berger A, Cellier C, Daniel C, et al. Small bowel metastases from primary carcinoma of the lung: clinical findings and outcome. *Am J Gastroenterol*. 1999 Jul; 94(7): 1884-7.
- 10) McNeill PM, Wagman LD, Neifeld JP. Small bowel metastases from primary carcinoma of the lung. *Cancer*. 1987 Apr 15; 59(8): 1486-9.
- 11) Kim SY, Ha HK, Park SW, et al. Gastrointestinal metastasis from primary lung cancer: CT findings and clinicopathologic features. *AJR Am J Roentgenol*. 2009 Sep; 193(3): W197-201.
- 12) Rossi G, Marchioni A, Romagnani E, et al. Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive Cases. *J Thorac Oncol*. 2007 Feb; 2(2): 115-20.
- 13) Japanese Society for Cancer of the Colon and Rectum. JSCCR Guidelines 2019 for the Treatment of Colorectal Cancer. Kinbara Publishing; 2019. p. 80-1. Japanese.
- 14) van Hooft JE, van Halsema EE, Vanbiervliet G et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. ESGE publishing. p. 994-7. Germany.
- 15) Boston Scientific Corporation homepage. Product introduction of HANAROSTENT Naturfit™. [Internet] 2017 Available from: https://www.bostonscientific.com/jp-JP/products/stent/HANAROSTENT_Naturfit.html

- 16) Hashimoto M, Yamamoto R. Endoscopic treatment for colon cancer using newly colon stent-report of two cases. *Prog Dig Endosc*. 2018; 92(1): 138-9
- 17) Ishibashi H, Goto M, Fujieda S et al. Tips for colonic stenting from our cases of perforation. *Progr Dig Endosc* 2018; 93(1): 35-40.
- 18) Xue XY, Zhou M, Fu WF, Pan YG, Zhao J. Colonic metastasis from primary lung adenocarcinoma: case report and review of the literature. *Med Oncol*. 2012 Jun; 29(2): 644-7.
- 19) Habaşoğlu MA, Oğuzülgen KI, Oztürk C, Akyürek N, Memiş L. A case of bronchogenic carcinoma presenting with acute abdomen. *Tuberk Toraks*. 2005; 53(3): 280-3.
- 20) Chen CH, Chen WM, Tung SY et al. Gastrointestinal metastasis from primary sarcomatoid carcinoma of the lung: a case report and review of the literature. *World J Surg Oncol*. 2015 May 8; 13: 174.
- 21) Parker NA, McBride C, Forge J, Lalich D. Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review. *World J Surg Oncol*. 2019 Apr 8; 17(1): 63.
- 22) Watt AM, Faragher LG, Griffin TT, Rieger NA, Maddern GY. Self-expanding Metallic Stents for Relieving Malignant Colorectal Obstruction: A Systematic Review. *Ann Surg*. 2007 Jul; 246(1): 24–30.
- 23) Lee PC, Lo C, Lin MT, Liang JT, Lin BR. Role of surgical intervention in managing gastrointestinal metastases from lung cancer. *World J Gastroenterol*. 2011 Oct 14; 17(38): 4314-20.
- 24) Liang TW, Sun Y, Wei YC, Yang DX. Palliative treatment of malignant colorectal obstruction caused by advanced malignancy: a self-expanding metallic stent or surgery? A system review and meta-analysis. *Surg Today*. 2014 Jan; 44(1) :22-33.

- 25) Ono H, Okabe M, Kimura T et al. Colonic metastasis from primary carcinoma of the lung: report of a case and review of Japanese literature. Clin J Gastroenterol. 2009 Apr; 2(2) :89-95.
- 26) Ishibashi H, Sato E, Iida M, Shigeru Yamazaki S. Rare metastasis of primary bronchogenic carcinoma to the ascending colon: a case report with cumulative study from the literature. J Jpn Surg Assoc. 1999; 60(12): 3228-33.

Figure legends

(Fig. 1) Computed tomography shows a mass in the left lower lung field (arrow).

(Fig. 2) Abdominal computed tomography demonstrates a mass in the colon at the hepatic flexure and intestinal dilatation proximal to the lesion (arrow).

(Fig. 3) Colonoscopy reveals a bulky tumor at the hepatic flexure. A self-expanding metallic stent was placed through the stenosis.

(Fig. 4) Histopathological findings for the primary lung tumor. Hematoxylin and eosin staining reveal large, polymorphic cells as well as densely infiltrating, proliferating atypical cells with distinct nucleoli (a: $\times 10$, b: $\times 40$).

Immunostaining shows positivity for CK7 (c) and negativity for CK20 (d), TTF-1 (e), and CDX-2(f).

CK; cytokeratin, TTF-1; thyroid transcription factor-1, caudal type homeobox 2; CDX-2

(Fig. 5) Histopathological findings for the colonic biopsies. Hematoxylin and eosin staining reveal large cells with polymorphic nuclei (a: $\times 10$, b: $\times 40$).

Immunostaining shows positivity for CK7 (c) and negativity for CK20 (d), TTF-1 (e), and CDX-2(f).

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5